



CDK2 inhibitors for cancer therapy and male contraception

CDK2 inhibitors for cancer therapy and non-hormonal male contraception with high selectivity and reduced side effects.

IP Status: US Patent Pending; Application No.: 18/216,497

Applications

- Cancer therapy
- Male contraception
- Research tool

Key Benefits & Differentiators

- **Increased Selectivity:** Allosteric inhibitors target a unique site, reducing off-target effects compared to traditional ATP-site inhibitors.
- **Dual Application:** Potential for use in both cancer chemotherapy and non-hormonal male contraception.
- **Reduced Side Effects:** Higher selectivity translates to fewer side effects, enhancing patient safety and treatment efficacy.

Technology Overview

Cyclin-dependent kinase 2 (CDK2) plays a crucial role in cell cycle regulation and is implicated in cancer progression and male fertility. While ATP-site binding inhibitors of CDK2 are known, they often lack selectivity, leading to side effects. The need for more selective inhibitors has driven the search for novel binding sites and mechanisms of inhibition.

Researchers at the University of Minnesota have developed new allosteric CDK2 inhibitors that bind outside the ATP site, leading to significant structural changes that prevent CDK2's association with its cyclin partners. These inhibitors have been optimized through structure-activity relationship (SAR) studies, resulting in highly potent nanomolar inhibitors. This breakthrough offers a targeted approach for cancer chemotherapy and a novel non-hormonal method for male contraception.

Phase of Development

TRL: 3-4

The researchers are currently optimizing these inhibitors for further in vivo testing.

Desired Partnerships

This technology is now available for:

- License
- Sponsored research
- Co-development

Please contact our office to share your business' needs and learn more.

Technology ID

2021-219

Category

All Technologies
Life Sciences/Biochemicals &
Small Molecules
Life Sciences/Human Health
Life Sciences/Pharmaceuticals
Life Sciences/Research Tools
Life Sciences/Therapeutics

Learn more



Researchers

- [Gunda I. Georg, PhD](#) Regents Professor, Department of Medicinal Chemistry

References

1. Erik B. Faber, Luxin Sun, Jian Tang, Emily Roberts, Sornakala Ganeshkumar, Nan Wang, Damien Rasmussen, Abir Majumdar, Laura E. Hirsch, Kristen John, An Yang, Hira Khalid, Jon E. Hawkinson, Nicholas M. Levinson, Vargheese Chennathukuzhi, Daniel A. Harki, Ernst Schönbrunn & Gunda I. Georg(2023) , <https://www.nature.com/articles/s41467-023-38732-x>, Nature Communications, 14, 3213
2. Erik B. Faber, Nan Wang, Kristen John, Luxin Sun, Henry L. Wong, David Burban, Rawle Francis, Defeng Tian, Kwon H. Hong, An Yang, Liming Wang, Mazen Elsaid, Hira Khalid, Nicholas M. Levinson, Ernst Schönbrunn, Jon E. Hawkinson, and Gunda I. Georg(2023) , <https://pubs.acs.org/doi/10.1021/acs.jmedchem.2c01731>, Journal of Medicinal Chemistry, 66, 1928-1940
3. Erik B Faber, Nan Wang, Gunda I Georg(2020) , <https://academic.oup.com/biolreprod/article/103/2/357/5858031>, Biology of Reproduction, 103, 357-367